JNCE Stock Overview
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.
Jounce Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.00|
|52 Week High||US$9.81|
|52 Week Low||US$2.76|
|1 Month Change||-26.29%|
|3 Month Change||-55.95%|
|1 Year Change||-54.41%|
|3 Year Change||-36.98%|
|5 Year Change||-78.99%|
|Change since IPO||-82.61%|
Recent News & Updates
Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|JNCE||US Biotechs||US Market|
Return vs Industry: JNCE underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: JNCE underperformed the US Market which returned -18.8% over the past year.
|JNCE Average Weekly Movement||12.8%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: JNCE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: JNCE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment.
Jounce Therapeutics Fundamentals Summary
|JNCE fundamental statistics|
Is JNCE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|JNCE income statement (TTM)|
|Cost of Revenue||US$46.11m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.97|
|Net Profit Margin||-400.91%|
How did JNCE perform over the long term?See historical performance and comparison
Is JNCE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JNCE?
Other financial metrics that can be useful for relative valuation.
|What is JNCE's n/a Ratio?|
Price to Sales Ratio vs Peers
How does JNCE's PS Ratio compare to its peers?
|JNCE PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
PIRS Pieris Pharmaceuticals
PBYI Puma Biotechnology
JNCE Jounce Therapeutics
Price-To-Sales vs Peers: JNCE is good value based on its Price-To-Sales Ratio (6.1x) compared to the peer average (90.7x).
Price to Earnings Ratio vs Industry
How does JNCE's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: JNCE is good value based on its Price-To-Sales Ratio (6.1x) compared to the US Biotechs industry average (13.7x)
Price to Sales Ratio vs Fair Ratio
What is JNCE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6.1x|
|Fair PS Ratio||2.7x|
Price-To-Sales vs Fair Ratio: JNCE is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).
Share Price vs Fair Value
What is the Fair Price of JNCE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate JNCE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate JNCE's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate JNCE's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Jounce Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JNCE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JNCE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JNCE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JNCE's revenue (58.4% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: JNCE's revenue (58.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if JNCE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Jounce Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: JNCE is currently unprofitable.
Growing Profit Margin: JNCE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: JNCE is unprofitable, and losses have increased over the past 5 years at a rate of 25.3% per year.
Accelerating Growth: Unable to compare JNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: JNCE has a negative Return on Equity (-53.82%), as it is currently unprofitable.
Discover strong past performing companies
How is Jounce Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: JNCE's short term assets ($164.8M) exceed its short term liabilities ($16.7M).
Long Term Liabilities: JNCE's short term assets ($164.8M) exceed its long term liabilities ($9.0M).
Debt to Equity History and Analysis
Debt Level: JNCE is debt free.
Reducing Debt: JNCE has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: JNCE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: JNCE has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 28% each year.
Discover healthy companies
What is Jounce Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate JNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate JNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if JNCE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if JNCE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as JNCE has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rich Murray (62 yo)
Dr. Richard Murray, also known as Rich, Ph D., has been the Chief Executive Officer, President and Director of Jounce Therapeutics, Inc., since July 10, 2014. Prior to joining Jounce, Dr. Murray serves as...
CEO Compensation Analysis
Compensation vs Market: Rich's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD1.75M).
Compensation vs Earnings: Rich's compensation has increased whilst the company is unprofitable.
Experienced Management: JNCE's management team is seasoned and experienced (9.3 years average tenure).
Experienced Board: JNCE's board of directors are considered experienced (6.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jounce Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Jounce Therapeutics, Inc.
- Ticker: JNCE
- Exchange: NasdaqGS
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$155.023m
- Shares outstanding: 51.67m
- Website: https://jouncetx.com
Number of Employees
- Jounce Therapeutics, Inc.
- 780 Memorial Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.